OrganTech is advancing its research and development in pursuit of our mission, guided by the objectives of a sustainable long-term plan. Our current R&D activities represent one stage within this ongoing process. As a research-driven company, we aim not only to contribute to the maintenance of human health and the enhancement of quality of life (QOL), but also to foster human progress and the creation of new industries for the future.
Between 2001 and 2015,
we developed the ‘Organ Germ Method,’ an innovative medical technology that, for the first time in the world, enabled the ex vivo manipulation of two types of stem cells required for organ regeneration. Notably, we demonstrated functional regeneration within the body of various organs located near the body surface, such as teeth, hair follicles, and secretory glands. These technologies have been accumulated and protected as intellectual property with the aim of future commercialization.
From 2016 to 2030,
we have been advancing the development of ‘regenerative medicine for all,’ focusing on organs such as teeth and hair, which can be commercialized at an early stage and possess strong market potential. Teeth and hair have a significant impact on human health and quality of life (QOL), and because treatments in these areas fall within the domain of private medical practice, they do not impose a substantial burden on national healthcare expenditures. In this way, we aim to establish new industries. In addition, as part of our research support initiatives, we are pursuing drug discovery assistance and healthcare product development using ‘three-dimensional artificial skin,’ an alternative to animal testing. Through these efforts, we promote product development grounded in robust scientific evidence.
From 2031 to 2050,
we aim to further advance organ regenerative medicine technologies to achieve the regeneration of internal organs and bring to fruition the commercialization of ‘life-regenerating medicine.’ Building on the achievements of next-generation biohybrid implants, we will demonstrate the concept of high-performance cyborgs by integrating metals with ligaments and skeletal control, thereby connecting ‘metallic arms and legs’ with muscles, tendons, and ligaments. Moreover, by advancing technologies for organ and tissue preservation to enable the control of entire organisms, we will expand into the development of innovations that contribute to medical applications of ‘artificial hibernation’ as well as ultra-long-duration space travel. In addition, through component analysis of human hair, we will establish health indicators and disease diagnostics, aiming to realize a society of autonomous health management.
